| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6121485 | Journal of Clinical Virology | 2013 | 5 Pages |
Abstract
Four doses of rituximab administered to individuals with early onset T1D decreased the incidence of asymptomatic EBV reactivations, as predicted by the rituximab-mediated elimination of memory B-cells, but increased the frequency of asymptomatic viremias caused by polyomaviruses.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Jing Lu Kroll, Craig Beam, Shaobing Li, Raphael Viscidi, Bonnie Dighero, Alice Cho, David Boulware, Mark Pescovitz, Adriana Weinberg, the Type 1 Diabetes TrialNet Anti CD-20 Study Group the Type 1 Diabetes TrialNet Anti CD-20 Study Group,